Every so often, an area of medical oncology has so many interesting presentations at a seminal conference that it becomes impossible to leave them out. At such times, Josh and Michael merely shrug their shoulders and say "why don't we do all of them." ESMO 2023 is one such instance. Despite their best efforts, our intrepid duo were unable to narrow down their presentation of early breast cancer highlights to one episode, so they are going to do two (for the price of one).

Articles discussed in this episode. Subscription may be required

• Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637956
• Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies
• https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637959
• Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637966

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.